3/2
10:00 am
evh
Rating for EVH
Medium
Report
Rating for EVH
3/2
10:00 am
evh
Rating for EVH
Medium
Report
Rating for EVH
2/26
03:22 pm
evh
Rating for EVH
Low
Report
Rating for EVH
2/26
03:22 pm
evh
Rating for EVH
Low
Report
Rating for EVH
2/26
02:11 pm
evh
Rating for EVH
Low
Report
Rating for EVH
2/25
11:34 am
evh
Rating for EVH
Medium
Report
Rating for EVH
2/25
11:34 am
evh
Rating for EVH
Medium
Report
Rating for EVH
2/25
10:19 am
evh
Rating for EVH
Low
Report
Rating for EVH
2/25
10:19 am
evh
Rating for EVH
Low
Report
Rating for EVH
2/25
10:07 am
evh
Evolent Health (EVH) had its "outperform" rating reaffirmed by BMO Capital Markets.
Low
Report
Evolent Health (EVH) had its "outperform" rating reaffirmed by BMO Capital Markets.
2/25
08:00 am
evh
Evolent Health (EVH) was downgraded by KeyCorp from "overweight" to "sector weight".
High
Report
Evolent Health (EVH) was downgraded by KeyCorp from "overweight" to "sector weight".
2/25
06:23 am
evh
Rating for EVH
High
Report
Rating for EVH
2/25
06:23 am
evh
Rating for EVH
High
Report
Rating for EVH
2/25
04:47 am
evh
Rating for EVH
High
Report
Rating for EVH
2/25
04:38 am
evh
Evolent Health downgraded to Sector Weight from Overweight at KeyBanc
High
Report
Evolent Health downgraded to Sector Weight from Overweight at KeyBanc
2/25
04:38 am
evh
Evolent Health downgraded to Sector Weight from Overweight at KeyBanc
High
Report
Evolent Health downgraded to Sector Weight from Overweight at KeyBanc
2/2
08:04 am
evh
Evolent Health (NYSE:EVH) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $10.00 price target on the stock, down previously from $16.00.
Low
Report
Evolent Health (NYSE:EVH) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $10.00 price target on the stock, down previously from $16.00.
2/2
05:39 am
evh
Rating for EVH
Low
Report
Rating for EVH
1/9
10:55 am
evh
Rating for EVH
Low
Report
Rating for EVH
1/9
10:55 am
evh
Rating for EVH
Low
Report
Rating for EVH
1/6
07:07 am
evh
Evolent Health (NYSE:EVH) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Evolent Health (NYSE:EVH) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..